CompletedNot Applicable

Effect of Orally Delivered Phytochemicals on Aging and Inflammation in the Skin

United States25 participantsStarted 2017-09-25

Plain-language summary

The objective is to determine, in a small number of participants, the protective effects of UV-induced skin erythema (reddening or "sunburn") following oral administration of sulforaphane, curcumin, or a combination of the two plant (diet)-based supplements. The investigators will be using the over-the-counter nutritional supplements Crucera-SGS and Meriva-SF to deliver the biologically stable sulforaphane precursor and a highly bioavailable formulation of curcumin. Volunteers will be challenged with UV irradiation at 2-times the minimum erythematous dose (M.E.D.) on discrete 2 cm diameter circles on the upper buttocks. Skin redness will be monitored daily using a chromometer. Biomarkers will then be evaluated in blood, urine, and skin biopsies.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18-70 years old, healthy * Willingness to avoid sun exposure to study site * Willingness to adhere to cruciferous vegetable-free diet Exclusion Criteria: * Use of photosensitizing medications * Use of medications that cause skin flushing * Use of anticoagulants/antiplatelet therapies * Allergies to anesthetic agents * Use of systemic retinoids or steroids (excluding female contraceptives and levothyroxin) * Topical retinoids or steroids at study sites * Antibiotic use * Current students of the Principal Investigator * Procedures performed at the study sites * Smokers/tobacco users

What they're measuring

Change in Erythema 1 Day After UV Exposure

Timeframe: On day 8 of intervention

Change in Erythema 2 Days After UV Exposure

Timeframe: On day 9 of intervention

Change in Erythema 3 Days After UV Exposure

Timeframe: On day 10 of intervention

Trial details

NCT IDNCT03289832

SponsorJohns Hopkins University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-10-23